Efficacy and Toxicity of Pemetrexed or Gemcitabine Combined with Cisplatin in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer
October 2012
in “
DOAJ (DOAJ: Directory of Open Access Journals)
”
TLDR Pemetrexed with cisplatin is safer and more effective than gemcitabine with cisplatin for advanced lung cancer.
The study compared pemetrexed (PP group) and gemcitabine (GP group) combined with cisplatin in 251 patients with advanced non-small cell lung cancer (NSCLC). The PP group had a higher total effective rate (25.20% vs. 17.74%) and significantly fewer adverse reactions, including reduced white blood cells, platelets, hemoglobin, and hair loss, compared to the GP group. Both groups had similar median survival times (16.9 vs. 17.0 months) and 1- and 2-year survival rates. The study concluded that pemetrexed combined with cisplatin was as effective as gemcitabine combined with cisplatin but had fewer side effects, making it a safer first-line treatment option for NSCLC.